RNA Avidity Biosciences Inc

Price (delayed)

$35.95

Market cap

$4.33B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.01

Enterprise value

$4.08B

Avidity Biosciences, Inc. is driven to change lives with a new class of therapies called Antibody Oligonucleotide Conjugates (AOCs) that are designed to overcome current limitations of oligonucleotide therapies in ...

Highlights
Avidity Biosciences's debt has decreased by 35% YoY and by 12% from the previous quarter
RNA's quick ratio is up by 33% YoY and by 6% from the previous quarter
The equity has soared by 60% YoY but it fell by 7% QoQ
RNA's net income has shrunk by 61% YoY and by 15% QoQ
RNA's revenue is down by 18% since the previous quarter and by 18% year-on-year

Key stats

What are the main financial stats of RNA
Market
Shares outstanding
120.54M
Market cap
$4.33B
Enterprise value
$4.08B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.25
Price to sales (P/S)
520.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
457.3
Earnings
Revenue
$8.93M
Gross profit
$8.93M
Operating income
-$433.27M
Net income
-$369.22M
EBIT
-$369.22M
EBITDA
-$363.01M
Free cash flow
-$365.22M
Per share
EPS
-$3.01
EPS diluted
-$3.01
Free cash flow per share
-$2.83
Book value per share
$11.05
Revenue per share
$0.07
TBVPS
$11.29
Balance sheet
Total assets
$1.46B
Total liabilities
$130.35M
Debt
$5.97M
Equity
$1.33B
Working capital
$1.35B
Liquidity
Debt to equity
0
Current ratio
16.91
Quick ratio
16.29
Net debt/EBITDA
0.69
Margins
EBITDA margin
-4,066.4%
Gross margin
100%
Net margin
-4,136%
Operating margin
-4,853.4%
Efficiency
Return on assets
-24.6%
Return on equity
-27%
Return on invested capital
-34.7%
Return on capital employed
-26.9%
Return on sales
-4,136%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RNA stock price

How has the Avidity Biosciences stock price performed over time
Intraday
4.02%
1 week
7.22%
1 month
23.84%
1 year
-22.57%
YTD
23.62%
QTD
26.58%

Financial performance

How have Avidity Biosciences's revenue and profit performed over time
Revenue
$8.93M
Gross profit
$8.93M
Operating income
-$433.27M
Net income
-$369.22M
Gross margin
100%
Net margin
-4,136%

RNA financials

RNA's operating margin has dropped by 107% year-on-year and by 40% since the previous quarter
Avidity Biosciences's net margin has plunged by 97% YoY and by 40% from the previous quarter
The operating income has plunged by 70% YoY and by 14% from the previous quarter
RNA's net income has shrunk by 61% YoY and by 15% QoQ

Price vs fundamentals

How does RNA's price correlate with its fundamentals

RNA Price vs fundamentals

RNA Earnings waterfall

RNA Price vs fair value

Growth

What is Avidity Biosciences's growth rate over time

RNA growth chart

Valuation

What is Avidity Biosciences stock price valuation
P/E
N/A
P/B
3.25
P/S
520.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
457.3

Valuation vs average

Price to earnings (P/E)

RNA's EPS is down by 4.2% from the previous quarter

Price to book (P/B)

The equity has soared by 60% YoY but it fell by 7% QoQ
The P/B is 30% above the 5-year quarterly average of 2.4 and 8% above the last 4 quarters average of 2.9

Price to sales (P/S)

RNA's P/S is 187% above its 5-year quarterly average of 174.2 and 18% above its last 4 quarters average of 424.3
RNA's revenue is down by 18% since the previous quarter and by 18% year-on-year

Efficiency

How efficient is Avidity Biosciences business performance
RNA's ROS has plunged by 97% YoY and by 40% from the previous quarter
RNA's return on invested capital is up by 37% year-on-year and by 4.7% since the previous quarter
The ROE has grown by 29% YoY but it has contracted by 4.2% from the previous quarter
RNA's ROA is up by 26% YoY but it is down by 5% from the previous quarter

Dividends

What is RNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNA.

Financial health

How did Avidity Biosciences financials performed over time

Assets vs liabilities

RNA's total assets has soared by 53% YoY but it is down by 7% QoQ
RNA's current ratio is up by 36% year-on-year and by 8% since the previous quarter

Debt vs equity

Avidity Biosciences's debt is 100% less than its equity
Avidity Biosciences's debt to equity has plunged by 100% YoY
The equity has soared by 60% YoY but it fell by 7% QoQ

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.